Related Experiment Video

Updated: Feb 22, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.7K

[Efficacy of pitavastatin on HDL-cholesterol]

Lale Tokgözoğlu1

  • 1Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey. lalet@hacettepe.edu.tr.

Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|September 28, 2017
PubMed

Insights

Low high-density lipoprotein (HDL) cholesterol predicts cardiovascular risk. Pitavastatin, a novel statin, enhances HDL functionality and promotes plaque regression, suggesting potential cardiovascular event reduction.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Low high-density lipoprotein (HDL) cholesterol is a significant predictor of cardiovascular risk, comparable to elevated low-density lipoprotein (LDL) cholesterol.
  • Emerging evidence highlights HDL functionality as a more critical determinant of cardiovascular health than mere HDL levels.
  • Statins, a class of drugs, are known to increase HDL levels and are hypothesized to improve HDL functionality.

Purpose of the Study:

  • To evaluate the impact of pitavastatin on HDL levels and functionality.
  • To investigate the effects of pitavastatin on atherosclerotic plaque regression.
  • To explore the potential of pitavastatin in reducing cardiovascular events.

Main Methods:

  • Comparative analysis of pitavastatin's effects on HDL parameters versus other statins.
  • Assessment of HDL functionality markers in patients treated with pitavastatin.
  • Imaging studies to evaluate atherosclerotic plaque changes following pitavastatin administration.

Main Results:

  • Pitavastatin demonstrated a superior increase in HDL levels compared to other statins.
  • Pitavastatin significantly enhanced HDL functionality.
  • Studies indicated that pitavastatin treatment led to atherosclerotic plaque regression.

Conclusions:

  • Pitavastatin exhibits a unique profile in elevating HDL levels and improving its functionality.
  • The observed plaque regression with pitavastatin supports its potential therapeutic role.
  • These findings suggest pitavastatin may offer a promising strategy for decreasing cardiovascular events.

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

478
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.7K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
473
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
596
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
545